

Debate: ¿Alternativas al algoritmo?

CÁNCER RENAL

PROGRAMA CIENTÍFICO

03 / SIMPOSIO SEOM

Personalizando el cáncer

Luis León

Complejo Hospitalario Pontevedra



MADRID 2014

22, 23 Y 24 OCTUBRE

HOTEL NH-EUROBUILDING

A black t-shirt is centered against a red background. The t-shirt has three large, irregular holes cut out of it, arranged in a triangular pattern. The holes are dark, suggesting they are deep. The text "LIVE AND LET DIE" is printed in white, bold, sans-serif capital letters across the chest area of the t-shirt.

LIVE AND LET DIE

Cáncer Renal Metastásico, 2007–2014

Opciones Terapéuticas



Sunitinib
Pazopanib
IFN- α +
bevacizumab
Temsirolimus

Axitinib
(post-sunitinib/citoquinas)
Everolimus
(post-VEGFR-TKI)
Sunitinib
(post-citoquinas)
Pazopanib
(post-citoquinas)
Sorafenib
(post-citoquinas)

Everolimus
(post-VEGFR-TKI
 $\times 2$)

Neoadyuvante

Adyuvante

Primera-línea

Segunda-línea

Tercera-línea

Pacientes elegibles

~100%

~40–60%^{1,2}

<20%^{3–5}

Resultados

PFS mediana
9–11 meses


PFS mediana
4–5 meses

PFS mediana
4–5 meses

IFN- α , interferon-alpha

Adaptado de Larkin. ASCO GU 2014

1. Levy *et al.* *Eur J Cancer* 2013; 2. Sonpavde *et al.* *Eur Urol* 2012; 3. Iacovelli *et al.* *Eur J Cancer* 2013; 4. Pal *et al.* ASCO GU 2013; 5. Heng *et al.* ASCO 2013.

B

B



Tratamiento combinado: pasado, presente, futuro

Pasado

Presente

Futuro

Combinaciones No efectivas:

INTORACT

Bevacizumab + temsirolimus¹

•BEST

Sorafenib + temsirolimus²

•RECORD 2

Bevacizumab + everolimus³

Nuevos estudios: inmunoterapia

+ agentes dirigidos

• CA 209-016

Nivolumab+ sunitinib/

sunitinib/pazopanib/ipilimumab⁴

1. Rini *et al.* ESMO 2012; 2. McDermott *et al.* JCO 2013;

3. Hainsworth *et al.* JCO 2010; 4. www.clinicaltrials.gov (NCT01472081)

¿Podemos utilizar marcadores para seleccionar el tratamiento?

Setting	Tumour markers	Treatment choice
First-line therapy	PDL1 expression	Anti-PD1-based therapy
	PDL1-/VHL null, BAP-1 WT	Selective VEGF inhibitor
	PDL1-/VHL null, BAP-1 mutant	VEGF inhibitor + agent 'X'
	mTOR activation, high LDH	TOR inhibitor
	Other mutation	Specific inhibitor
Second-line therapy	Not necessary	

BAP-1, BRCA1 associated protein-1; LDH, lactate dehydrogenase; mTOR, mammalian target of rapamycin; PD1, programmed cell death 1; PDL1, programmed death ligand 1; TOR, target of rapamycin; VEGF, vascular endothelial growth factor; VHL, Von Hippel–Lindau.


THE ROLLING STONES

TIME IS ON MY SIDE


b/w CONGRATULATIONS



Hallmarks of Cancer: dianas terapéuticas



Hallmarks of Cancer: dianas terapéuticas



Debate: ¿Alternativas al algoritmo?

PROGRAMA CIENTÍFICO

03 / SIMPOSIO SEOM

Personalizando el cáncer

Luis León

Complejo Hospitalario Pontevedra



MADRID 2014 / 22, 23 Y 24 OCTUBRE / HOTEL NH-EUROBUILDING